CL2022002899A1 - Heteroarilo halogenado y otros inhibidores de cinasas heterocíclicas y usos de los mismos - Google Patents
Heteroarilo halogenado y otros inhibidores de cinasas heterocíclicas y usos de los mismosInfo
- Publication number
- CL2022002899A1 CL2022002899A1 CL2022002899A CL2022002899A CL2022002899A1 CL 2022002899 A1 CL2022002899 A1 CL 2022002899A1 CL 2022002899 A CL2022002899 A CL 2022002899A CL 2022002899 A CL2022002899 A CL 2022002899A CL 2022002899 A1 CL2022002899 A1 CL 2022002899A1
- Authority
- CL
- Chile
- Prior art keywords
- kinase inhibitors
- inhibitors
- structurally similar
- dasatinib
- abl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La invención se refiere a inhibidores de cinasa, en particular inhibidores de la proteína cinasas que incluye la superfamilia SIK CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT y/o sus mutantes. Aunque estructuralmente similares al dasatinib, los inhibidores de cinasa de la invención son distintivos; poseen una clase particular de heteroarilos halogenados. Estos inhibidores de cinasa pueden mostrar una o más ciertas propiedades distintas al dasatinib y otros inhibidores de cinasa estructuralmente similares. Los inhibidores de cinasa de la invención o composiciones farmacéuticas que los comprenden se pueden usar en el tratamiento de un trastorno o afección, tal como un trastorno proliferativo, por ejemplo, una leucemia o tumor sólido. En particular, estos y otros inhibidores de cinasa estructuralmente similares se pueden usar en el tratamiento de un trastorno proliferativo - tal como una leucemia aguda fenotípica mezclada (MPAL) - caracterizada por (entre otras cosas) la presencia de la proteína MEF2C, una translocación cromosómica humana en 11q23, y/o una oncoproteína de fusión KMT2A. Los inhibidores de cinasa o composiciones farmacéuticas descritas en la presente se pueden usar tópicamente para modular la pigmentación de la piel en un sujeto, por ejemplo para impartir protección UV y reducir el riesgo de cáncer de piel.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20170641.3A EP3901151A1 (en) | 2020-04-21 | 2020-04-21 | Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002899A1 true CL2022002899A1 (es) | 2023-06-30 |
Family
ID=71108343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002899A CL2022002899A1 (es) | 2020-04-21 | 2022-10-20 | Heteroarilo halogenado y otros inhibidores de cinasas heterocíclicas y usos de los mismos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20230348453A1 (es) |
EP (2) | EP3901151A1 (es) |
JP (1) | JP2023522124A (es) |
KR (1) | KR20230015343A (es) |
CN (1) | CN115667255A (es) |
AU (1) | AU2021258431A1 (es) |
BR (1) | BR112022021476A2 (es) |
CA (1) | CA3176325A1 (es) |
CL (1) | CL2022002899A1 (es) |
CO (1) | CO2022016245A2 (es) |
CR (1) | CR20220528A (es) |
IL (1) | IL297481A (es) |
MX (1) | MX2022013160A (es) |
PE (1) | PE20230462A1 (es) |
TW (1) | TW202204352A (es) |
WO (1) | WO2021214117A1 (es) |
ZA (1) | ZA202212631B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023067021A1 (en) * | 2021-10-19 | 2023-04-27 | Iomx Therapeutics Ag | A synthesis scheme and procedures for preparing a sik3 inhibitor and intermediates thereof |
US20230212246A1 (en) * | 2022-01-05 | 2023-07-06 | The Board Of Regents Of The University Of Texas System | Tgf-b as a therapeutic target for intracranial aneurysm |
EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
EP4257132A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Sik3 inhibitors for treating diseases resistant to death receptor signalling |
CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4475916A (en) | 1982-03-18 | 1984-10-09 | Merck & Co., Inc. | Osmotic drug delivery system |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
EP1841431A4 (en) | 2005-01-26 | 2009-12-09 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
EP2061468A4 (en) | 2006-09-11 | 2011-05-04 | Curis Inc | TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AU2015300782B2 (en) | 2014-08-08 | 2020-04-16 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (SIK) inhibitors |
CN106699744B (zh) * | 2015-11-18 | 2021-05-11 | 四川海思科制药有限公司 | 一种杂环类酰胺衍生物及其制备方法和在药学上的应用 |
RU2019129727A (ru) | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
EP3643713A1 (en) * | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
-
2020
- 2020-04-21 EP EP20170641.3A patent/EP3901151A1/en active Pending
-
2021
- 2021-04-21 AU AU2021258431A patent/AU2021258431A1/en active Pending
- 2021-04-21 KR KR1020227040346A patent/KR20230015343A/ko active Search and Examination
- 2021-04-21 US US17/996,514 patent/US20230348453A1/en active Pending
- 2021-04-21 TW TW110114388A patent/TW202204352A/zh unknown
- 2021-04-21 CN CN202180027921.5A patent/CN115667255A/zh active Pending
- 2021-04-21 WO PCT/EP2021/060338 patent/WO2021214117A1/en unknown
- 2021-04-21 CR CR20220528A patent/CR20220528A/es unknown
- 2021-04-21 IL IL297481A patent/IL297481A/en unknown
- 2021-04-21 BR BR112022021476A patent/BR112022021476A2/pt unknown
- 2021-04-21 JP JP2022563872A patent/JP2023522124A/ja active Pending
- 2021-04-21 PE PE2022002448A patent/PE20230462A1/es unknown
- 2021-04-21 CA CA3176325A patent/CA3176325A1/en active Pending
- 2021-04-21 EP EP21718920.8A patent/EP4139305A1/en active Pending
- 2021-04-21 MX MX2022013160A patent/MX2022013160A/es unknown
-
2022
- 2022-10-20 CL CL2022002899A patent/CL2022002899A1/es unknown
- 2022-11-11 CO CONC2022/0016245A patent/CO2022016245A2/es unknown
- 2022-11-21 ZA ZA2022/12631A patent/ZA202212631B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021258431A1 (en) | 2022-11-17 |
EP4139305A1 (en) | 2023-03-01 |
MX2022013160A (es) | 2023-02-09 |
WO2021214117A1 (en) | 2021-10-28 |
IL297481A (en) | 2022-12-01 |
JP2023522124A (ja) | 2023-05-26 |
PE20230462A1 (es) | 2023-03-14 |
ZA202212631B (en) | 2023-07-26 |
EP3901151A1 (en) | 2021-10-27 |
CA3176325A1 (en) | 2021-10-28 |
CO2022016245A2 (es) | 2023-02-27 |
US20230348453A1 (en) | 2023-11-02 |
BR112022021476A2 (pt) | 2023-04-04 |
TW202204352A (zh) | 2022-02-01 |
KR20230015343A (ko) | 2023-01-31 |
CN115667255A (zh) | 2023-01-31 |
CR20220528A (es) | 2023-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022016245A2 (es) | Heteroarilo halogenado y otros inhibidores de cinasas heterocíclicas y usos de los mismos | |
CO2022001453A2 (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
WO2021219731A3 (en) | Bicyclic kinase inhibitors and uses thereof | |
CO2019011873A2 (es) | Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats | |
GT201400113A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
CO2021017981A2 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer | |
PE20152000A1 (es) | Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico | |
CL2021001722A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
CL2012003680A1 (es) | Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico. | |
ECSP109957A (es) | Derivados de pirimidinil-piridazinona. | |
CL2011000880A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer. | |
CL2021001721A1 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
DOP2005000014A (es) | Derivados 1h-tieno[2, 3-c] pirazol utiles como inhibidores de quinasa | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
PE20191486A1 (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER | |
CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
ECSP099539A (es) | Derivados de 3-cinolinacarboxamida y su uso para tratar el cáncer | |
CO2023012903A2 (es) | Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2) | |
MX2018008507A (es) | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). |